(Q69431200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

title

Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

1 reference

acute myeloid leukemia

1 reference

1 reference

A Wahlin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

publication date

1 January 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

Medical oncology and tumor pharmacotherapy

1 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

page(s)

199-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2615524%20AND%20SRC:MED&resulttype=core&format=json

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.

1 October 2019

cites work

1 reference

12 December 2020

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

12 December 2020

A phase I and II study of m-AMSA in acute leukaemia.

1 reference

12 December 2020

Refractory dysmyelopoietic anemia and acute leukemia

1 reference

12 December 2020

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults

1 reference

12 December 2020

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

12 December 2020

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

12 December 2020

Therapy of acute myelogenous leukemia

1 reference

12 December 2020

Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

1 reference

12 December 2020

A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia

1 reference

12 December 2020

Post-remission therapy in acute myeloid leukemia

1 reference

12 December 2020

A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Proposals for the classification of the myelodysplastic syndromes

1 reference

12 December 2020

Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.

1 reference

12 December 2020

Etoposide-cytarabine therapy for acute leukemia following myelodysplastic syndromes or secondary to treatment for malignant diseases

1 reference

12 December 2020

Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission

1 reference

12 December 2020

Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. The Toronto Leukemia Study Group

1 reference

12 December 2020

Treatment of patients with acute nonlymphocytic leukemia not in remission

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02985191

0 references

1 reference